Redeye provides an update following Paxman’s Q2 2026 report.
Redeye provides an initial take following Paxman’s Q2 2026 report.
Redeye comments on Paxman’s FDA process on its CIPN device.
Redeye presents its preview for Paxman’s Q2 2026 report, due on August 21.
Redeye views CMS’s proposed 2027 reimbursement rules as a step in the right direction.
Redeye is positive about Paxman’s regulatory clearance in the EU and UK for its CIPN device.
Redeye provides an update following Paxman’s Q1 2026 report.
Redeye provides an initial take following Paxman’s Q1 2026 report.
Redeye presents its preview for Paxman’s Q1 2026 report, due on May 21.
The Top Picks Investment Committee remains active in a market that has finally started to move after a prolonged period of sluggishness.
Redeye provides an initial take following Paxman’s Q4 2025 report.
Redeye is positive on the new CPT III codes for Paxman’s CIPN device.
Redeye presents its preview for Paxman’s Q4 2025 report, due on February 27.
Redeye provides a summary of Paxman’s CMD. The event offered no material surprises and introduced little new information; however, it did pr...
Redeye comments on CMS’s finalised reimbursement rates, effective from January 2026.
Redeye provides an update following Paxman’s Q3 2025 report.
Redeye provides an initial take following Paxman’s Q3 2025 report.
Redeye presents its preview for Paxman’s Q3 2025 report, due on November 14.
Redeye is positive about the updated data from Paxman’s CIPN clinical trial in Singapore.
Redeye is positive about the acceptance of Paxman’s PLCS system for CIPN into the FDA’s Safer Technologies Program (SteP).
Redeye comments on Glenn Paxman’s ownership reduction.
Redeye provides an update following Paxman’s Q2 2025 report.
Redeye provides an initial take following Paxman’s Q2 2025 report.
Redeye presents its preview for Paxman’s Q2 2025 report, due on August 20.
Redeye comments on CMS’s preliminary CPT-I codes payment rates.
Redeye provides an update following Paxman’s Q1 2025 report.
Redeye provides an initial take following Paxman’s Q1 2025 report.
Redeye provides a brief comment on Paxman’s announcement to complete the offer for Dignitana.
Redeye returns with an update following Paxman’s takeover offer to Dignitana and the directed share issue.
Redeye comments on Paxman’s directed issue to institutional investors, raising SEK123.
Redeye comments on Paxman’s takeover offer to Dignitana, valued at approximately SEK153m, representing a 81% premium compared to yesterday’s...
Redeye saw a report with sales that were lower than our expectations.
Redeye saw a sales development that was just below our expectations.
Redeye is positive to the news regarding the support from a new law in New York state for insurance coverage from private health insurers, w...
Redeye saw a sales development that was lower than expected.
Redeye comments on the proposed increased rate for Medicare and Medicaid for 2025 under the OPPS and ASC payment systems.
Redeye comments on the announcement of the achievement of a significant milestone as AMA Issues Permanent CPT® Category I Codes for Scalp Co...
Redeye views favorably the announcement of the first order from the US Department of Veterans Affairs in the previously announced contract a...
Redeye saw a report with sales that were in line with better-than-expected results.
Redeye saw a sales development roughly in line with what was expected.
Redeye comments on the Paxman contract with the US Veterans Association as a sole contractor with the supplier awarded the contract.
Redeye comments on the published interim data from the MASCC/AFSOS/ISOO 2004 annual meeting in Lille on Saturday, based on the Single-arm ph...
Redeye saw a report with more robust sales and results than expected.
Redeye saw a sales development that was stronger than expected.
Redeye saw a report with softer sales and results than we expected.
Redeye saw a sales development that was a bit softer than expected.
Redeye is impressed by the continued strong growth and result progression that was better than expected.
Redeye is impressed by the continued strong sales development with a beat of our sales estimates.
Redeye comments on the decision by CMS to decrease the average rate for 2024 under the Hospital Outpatient Prospective Payment System and Am...
Redeye comments on the news that the first Medicare Administrative Contractor (MAC) has approved the proposed Local Coverage Determination (...
Redeye sees continued strong sales progression driven by the right underlying factors.
Redeye continues to see strong sales development with a beat of our sales estimates.
Redeye comments on the news that a Medicare Administrative Contractor (MAC) has issued a proposed Local Coverage Determination (LCD) in the ...
Redeye sees continued sales progression driven by the right underlying factors.
Redeye continues to see strong sales development. On the other hand, the costs were slightly higher in the quarter, primarily other operatin...
Redeye sees a report that continues to show strong sales development.
Redeye is favorable to the news that Paxman has received its EU Medical Device Regulation certification.
Redeye sees a report that continues to show stronger sales development than expected.
Redeye is pleased that Paxman announced yesterday that the Paxman Limb Cryocompression System (PLCS) would be used in a prospective study lo...
Paxman announced yesterday that the Paxman Limb Cryocompression System (PLCS) would be used in a prospective study looking at the prevention...
Redeye comments on the confirmation of the CMS payment rate for Scalp Cooling for 2023 that sends a strong message to MACs and providers.
Redeye is impressed by the sales progression in the past quarter.
Redeye sees a report that showed considerably stronger sales development in the quarter than expected.
Redeye sees a weaker report than expected due to supply chain delays and covid issues that made order fulfillment slower than expected.
Redeye comments on the letter of interest with Concord Medical in China.
Redeye is encouraged by the strong momentum in the business.
Redeye sees a stronger-than-expected report where growth momentum and return to a positive result are the main points.
Redeye comments on Paxman's Q1 report. Continued progress and increasing sales.
